SAB Biotherapeutics (SABS) Net Equity Issued and Repurchased (2020)
SAB Biotherapeutics' (SABS) quarterly Net Equity Issued and Repurchased came in at $25000.0 in Q4 2020.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Net Equity Issued and Repurchased (2020) Analysis & Trends
SAB Biotherapeutics (SABS) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $25000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | - |